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We have constructed an optimized mutant of the kappa
opioid receptor (KOR), which is devoid of its 10 free
cysteines. It was necessary to test different amino acid
replacements at various positions and we used a structural
model and homology with other receptor family members
as a guide. This mutant binds ligands and couples to the
cognate G-proteins in a very similar fashion to wild-type
KOR. The addition of the antagonist naloxone during cell
growth greatly enhances heterogeneous expression of the
mutant in mammalian cells, such that amounts similar to
wild-type could be produced. We showed by ¯uorescence
microscopy that naloxone stabilizes the mutant in the
plasma membrane. This mutant, which now permits the
insertion of single cysteines, was designed for use in spec-
troscopic studies of ligand-induced receptor conforma-
tional changes as well as to simplify folding studies.
Keywords: cysteine replacement/G protein-coupled receptor/
membrane proteins/protein design
Introduction
The kappa opioid receptor (KOR) is a member of the peptide-
binding subfamily of class A of G protein-coupled receptors
(GPCRs) and couples to Gi, Go and Gz proteins (Prather et al.,
1995; Tso and Wong, 2000). Major cellular manifestations of
receptor-mediated signaling are the inhibition of adenylyl
cyclase activity, the inhibition of voltage-dependent Ca2+
channels and the increase in K+ conductance (Satoh and
Minami, 1995; Standifer and Pasternak, 1997). The receptor
mediates many important physiological functions, such as
modulation of pain, drinking, water balance, food intake, gut
motility, temperature control and various endocrine functions.
Furthermore, in humans, activation of KOR has been found to
produce dysphoria and psychotomimesis (Meng et al., 1993).
Agonists selective for KOR produce an effective analgesia
without the substantial side effects (constipation, respiratory
depression, vomiting and physical dependence) associated with
mu opioid receptor agonists such as morphine (Reece et al.,
1994).
Despite extensive studies on structure±function relationships
using receptor chimeras of the related kappa, mu and delta
opioid receptors (Kong et al., 1994; Wang et al., 1994; Xue
et al., 1994, 1995; Chen et al., 1995; Liu et al., 1995; Meng
et al., 1995, 1996; Minami et al., 1995; Hjorth et al., 1996; Zhu
et al., 1996; Coward et al., 1998; Lu et al., 1998; Seki et al.,
1998; Mollereau et al., 1999) and ample work on KOR
mutagenesis, focused on receptor desensitization, internaliza-
tion and down-regulation (Appleyard et al., 1999; Li,J. et al.,
2002; Li,J.G. et al., 2002; Schulz et al., 2002; Zhang et al.,
2002), activation (Thirstrup et al., 1996; Standifer and
Pasternak, 1997) and the location of the ligand-binding pocket
(Hjorth et al., 1995; Jones et al., 1998; Xu et al., 2001), detailed
structural understanding of signal transduction mediated by
KOR remains elusive. Clearly, this is primarily because a direct
investigation of the opioid receptor tertiary structure by
crystallography or NMR has not been achieved. It has been
reported in numerous studies (Ruegg et al., 1982; Itzhak et al.,
1984; Gioannini et al., 1985; Demoliou-Mason and Barnard,
1986; Simon et al., 1985, 1986, 1987) that this receptor forms
higher order aggregates when extracted from the membrane-
embedded form using detergents, at least under the described
experimental conditions. This behavior makes even 2-D
crystallization dif®cult. Recently, it was shown by biolumines-
cence resonance energy transfer in vivo that KOR constitu-
tively forms oligomers in HEK293 cells under conditions
where the receptor is overexpressed (Ramsay et al., 2002). All
of these studies suggest that the receptor is prone to aggrega-
tion.
For these reasons, the agonist-induced conformational
changes of the opioid receptors might best be studied by
¯uorescence spectroscopy in vitro using arti®cial bilayers with
immobilized receptor. In particular, ¯uorescent probes are
known (Gether et al., 1995) which change their ¯uorescent
properties depending on the hydrophobicity of the environ-
ment. One of the most convenient site-speci®c modi®cations is
a coupling to cysteine. This approach was pioneered on the b2-
adrenergic receptor (Gether et al., 1997; Ghanouni et al., 2001;
Neumann et al., 2002) by exploiting the distinct reactivity of
the endogenous sulfhydryl groups. Another approach for
studying agonist-induced conformational changes might be
the use of an in situ disul®de cross-linking strategy, which was
employed in the case of the M3 muscarinic acetylcholine
receptor (Zeng et al., 1999; Ward et al., 2002).
To make these approaches fully general, one needs to be able
to introduce free cysteines at desired positions in the sequence.
Most GPCRs have a large number of endogenous cysteines,
which would preclude selective labeling at a newly engineered
cysteine. Therefore, a prerequisite for the designed introduc-
tion of a unique free cysteine into a receptor at a speci®c
position is the creation of a cysteine-free receptor or else the
simultaneous labeling of endogenous free cysteines may cloud
the interpretation of the experimental data (Javitch et al.,
2002). However, a cysteine-free GPCR has not yet been
reported.
Almost all GPCRs are thought to contain a conserved
disul®de bond, connecting the transmembrane helix 3 and the
second extracellular loop. The sensitivity of the opioid
receptors to DTT in neuronal membrane preparations was
reported to decrease in the order m > d >> k, which the authors
interpreted to mean that the disul®de bridge may not be crucial
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for the function of KOR (Gioannini et al., 1989). However, it
was not directly demonstrated in these studies that the putative
disul®de bond was actually reduced. Zhang et al. mutated
highly conserved cysteines, believed to form a disul®de bond,
in human mu opioid receptor (MOR) to alanine and serine
(Zhang et al., 1999). Ligand binding was lost, but the receptor
was still expressed in the cell. Xu et al. successfully replaced
individual transmembrane cysteines of human delta opioid
receptor (DOR), human KOR and rat MOR with serine and one
additional cysteine, present in rat MOR only, with methionine
(Xu et al., 2000).
An initial experiment in which we replaced all free
endogenous cysteines of KOR at once with alanine indicated
a total loss of activity, even when keeping the potential
disul®de bond (see below). However, we report here a strategy
for ®nding optimized replacements for all free cysteine
residues and we combined them to generate a ®nal free-
cysteine-less (FCL) mutant. Its expression level was enhanced
by exploiting ligand-mediated receptor up-regulation, de-
scribed recently (Li et al., 2001a,b). The ligand binding and
G-protein coupling characteristics of the wild-type (WT) and
the FCL receptors were compared. We also studied the cellular
localization of the receptor by means of cytoimmunochemistry.
Materials and methods
Materials
Reagents were obtained from Sigma, Fluka or Merck, unless
stated otherwise. Tris was from Serva and forskolin and
IBMX (3-isobutyl-1-methylxanthine) were from Calbiochem.
Dynorphin A(1±13) (Tyr±Gly±Gly±Phe±Leu±Arg±Arg±Ile±
Arg±Pro±Lys±Leu±Lys) was from Bachem and a stock solu-
tion was prepared in 50% (v/v) aqueous methanol containing
HCl (50 mM) (Goldstein, 1984). Stock solutions of the MOR
agonist DAMGO (Tyr±D-Ala±Gly±N-methyl±Phe±Gly-ol), the
KOR agonist (±)-trans-1S,2S-U-50488 hydrochloride (here-
after U-50488) and the opioid antagonists naloxone hydro-
chloride (hereafter naloxone) (Blumberg et al., 1961; Foldes
et al., 1963) and naltrexone were prepared in water. An inverse
agonist of KOR, annotated in the original paper (Becker et al.,
1999) as Peptide I (structure in ®gure 8 of Becker et al., 1999)
was kindly provided by Dr A.Pessi (IRBM P. Angeletti, Rome,
Italy); a stock solution was prepared in DMSO.
Construction of receptor variants
The cDNA of rat KOR-subtype 1 (NCB accession No. P34975)
(Minami et al., 1993) was a gift from Dr M.Satoh (Kyoto
University, Kyoto, Japan). The internal HindIII site was
removed by overlapping PCR and the gene was ®rst cloned
into the mammalian expression vector pcDNA3.1 (Invitrogen)
with a C-terminal hexahistidine tag. This construct was used as
a template for further manipulation and mutagenesis. Every
cysteine substitution was introduced using a set of two
complementary primers, each about 40 nucleotides long with
a mutation in the middle. The mutated gene was assembled by
overlapping PCR and used to replace the original gene in the
template using two internal restriction sites ¯anking the
mutated part of the template. Other tagged constructs were
prepared as follows. First, the receptor was recloned into the
pcDNA3.1a(±)/myc/His vector in frame with C-terminal myc
and His tags, both encoded in the vector. For the WT and FCL
receptors, the ®rst three N-terminal amino acids were replaced
by a FLAG tag (MDYKDDDDK), followed by a glycine. This
N-terminal FLAG tag was previously shown not to affect the
signaling of KOR (Li,J., et al., 2002). HindIII sites were
introduced at both ends of the enhanced green ¯uorescent
protein gene (eGFP from vector pEGFP-N3; Clontech) using
PCR, and the eGFP gene was fused to the receptor gene at the
HindIII site, present on the vector. Therefore, the residues Lys-
Leu were inserted between KOR and eGFP and also between
eGFP and the C-terminal myc/His tag. For use with the Flp-
InÔ System (see below), the receptor with the FLAG tag on its
N-terminus and a decahistidine tail on its C-terminus was
subcloned into the pcDNA5/FRT vector (Invitrogen). The
Escherichia coli strain XL1-Blue (Stratagene) was used for the
ampli®cation of DNA. All constructs were con®rmed by DNA
sequencing.
Cell culture
Cell lines HEK293T (a clonal line of HEK 293 cells stably
expressing the SV40 large T antigen) and COS-1 (both ATCC)
were grown in Dulbecco's modi®ed Eagle medium (DMEM)
with high glucose (Sigma, Cat. No. D 6429) in the presence of
10% (v/v) heat-inactivated fetal calf serum (EC approved;
Invitrogen) and 5% CO2 at 37°C in a humidi®ed incubator.
Cells were routinely seeded into 24-well cell culture plates in
0.5 ml of medium and grown for 24 h, reaching 80±95%
con¯uence, prior to transfection. Flp-InÔ-293 cells
(Invitrogen) were grown in the presence of selection antibiotics
under the same conditions.
Transient transfection
Cells were transfected with DNA using calcium phosphate
precipitation based on the original protocol (Graham and van
der Eb, 1973) with a small modi®cation as follows. First, 25 ml
of CaCl2 (500 mM) was mixed with 1 mg of DNA. To this
solution, 25 ml of a buffer containing 1.5 mM Na2HPO4,
140 mM NaCl, 50 mM HEPES, pH 7.05, were added. The
mixture was then incubated for 60 s at room temperature and
added dropwise to a well with cells overlaid with 0.5 ml of
medium. Four hours later, the medium was exchanged and cells
were further grown for 20 h in the absence or presence of
naloxone (30 mM). Cells were harvested, washed three times
with 0.5 ml of PBS and frozen in liquid nitrogen. Cell pellets
were stored at ±80°C.
Isogenic stable cell line generation based on polyclonal
selection
The Flp-InÔ System based on Flp recombinase-mediated
gene site-speci®c integration [O'Gorman et al. (1991) and
www.invitrogen.com] was used as follows. The Flp-InÔ-293
cell line with a single chromosomal Flp recombination target
site was expanded in medium containing Zeocin (100 mg/ml).
One day prior to transfection, 53105 cells were seeded per well
in a six-well plate in 2 ml of medium without Zeocin. Co-
transfection using Lipofectamine-2000 (Invitrogen) was per-
formed as follows. The plasmid pcDNA5/FRT encoding the
WT or FCL receptor (200 ng) and the plasmid pOG44
encoding Flp recombinase (1.8 mg) were resuspended in
OptiMEMâ I Reduced Serum Medium (250 ml).
Lipofectamine-2000 (6 ml) was resuspended in a separate
aliquot of OptiMEMâ I Reduced Serum Medium (250 ml) and
incubated for 5 min at room temperature. Both aliquots were
mixed, incubated for 20 min at room temperature and added
dropwise to the growth medium (1.5 ml). The medium was
exchanged 24 h later. After a further 24 h, cells were
trypsinized, transferred to a 10 cm dish and grown for 1 week
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in the presence of the selection antibiotic Hygromycin B (100
mg/ml). The selection medium was exchanged every second
day. All remaining cells were trypsinized and transferred into
one 22 mm well and grown for 14 days until a few large
colonies were identi®ed. Cells were trypsinized and transferred
as a pool into one 35 mm well. Cells were grown to 95%
con¯uence, then trypsinized and transferred to a 75 cm2 tissue
culture ¯ask and further expanded.
Binding assays with radioligand on whole cells
Binding assays were carried out essentially as described
previously (Ruegg et al., 1982) with a small alteration in the
®ltration step. Cell pellets were resuspended in 500 ml of Tris±
HCl buffer (50 mM), pH 7.4, with 1 mM EDTA (TE buffer)
and 1 nM [3H]diprenorphine (58 Ci/mmol) (Amersham
Pharmacia Biotech). Non-speci®c binding was determined in
the presence of 10 mM naloxone. The suspension (200 ml) was
routinely incubated at room temperature for 45 min. Where
indicated, the suspension was incubated at 4°C for 4 h.
Separation of free and bound ligand was performed on a
®ltration vacuum manifold (Millipore) using 96-well ®ltration
plates with glass-®ber ®lters (MAFBNOB plate from
Millipore) pretreated with 0.5% (v/v) polyethylenimine
(Bruns et al., 1983). The ®lters were quickly washed with
1 ml of ice-cold TE buffer. OptiPhase HiSafe 2 scintillation
cocktail (Wallac) was added directly to the wells (100 ml/well).
The plate was shaken overnight and radioactivity was counted
in a liquid scintillation counter (1450 Microbeta Plus, Wallac).
Non-speci®c binding in the case of WT was <5% of total
binding.
Membrane preparation
A rinsed pellet of transfected cells (from a con¯uent 75 cm2
cell culture dish) grown in the presence of naloxone was
resuspended in 3 ml of homogenization buffer (HB) containing
11% (w/v) sucrose, 10 mM MgCl2 and 0.3% (v/v) protease
inhibitor cocktail (Sigma, Cat. No. P-8340) in TE buffer. Cells
were lysed using a 7 ml Dounce tissue grinder, with a tight
piston (Wheaton) for 30 strokes. The suspension was
centrifuged for 10 min at 4°C at 2300 r.p.m. (1100 g) in a
Sigma 4K15 centrifuge. The pellet was resuspended in 3 ml of
HB and the suspension was again treated with the Dounce
tissue grinder and centrifuged for 10 min at 2300 r.p.m. The
supernatants from the ®rst and the second centrifugation steps
were pooled and centrifuged for 1 h at 4°C at 31 000 r.p.m.
(40 000 g) in a Beckman Optima TLX ultracentrifuge. The
pellet was rinsed with 2 ml of HB, resuspended in 750 ml of HB
using a Dounce tissue grinder, frozen in liquid nitrogen and
stored at ±80°C. Total membrane protein concentrations were
determined using the Bio-Rad DC protein assay with bovine
serum albumin as a standard.
Binding assays with radioligand on membrane preparations
Membrane proteins were diluted to 5 mg/ml in TE buffer with
various concentrations of [3H]diprenorphine. Non-speci®c
binding was determined in the presence of 10 mM naloxone.
For calculating the receptor level and the apparent equilibrium
dissociation constant (KD) from the saturation binding data, we
used a single-site binding model. In inhibition binding assays,
concentrations of 0.25 nM [3H]diprenorphine and 5 mg/ml total
membrane protein were used. Typically, samples of 800 ml
were used for ®ltration, as in the binding assay with whole cells
described above. Inhibition data were ®tted to a single-site
binding model with reversible inhibition by using non-linear
least-squares regression in order to obtain best estimates for Rt
(total receptor concentration) and KI (equilibrium inhibition
constant of the non-radioactive ligand to be tested). Data were
®tted by solving the following equation for C (equilibrium
concentration of receptor±radioligand complex) by using the
program MATLAB:
KDC  LF RT ÿ C ÿ KDCIT
KILT  KD ÿ KIC
 
1
The parameter LF (free equilibrium radioligand concentration)
can be approximated with LT (total radioligand concentration),
since in our radioligand inhibition assays the concentrations LT
and LF did not vary by more than 5%. KD (equilibrium
dissociation constant of the radioligand) was determined
independently in the radioligand saturation binding assay and
then kept constant. IT (total inhibitor concentation) is an
independent variable.
SDS±PAGE and western blotting
Pellets of 33105 cells from con¯uent wells in 24-well plates
were resuspended in 50 ml of ice-cold radioimmunoprecipita-
tion assay (RIPA) buffer (Brugge and Erikson, 1977) [our
modi®ed RIPA buffer contained 1% (w/v) Nonidet P-40, 0.5%
(w/v) sodium deoxycholate and 0.1% (w/v) SDS in PBS, pH
7.4] and incubated for 10 min on ice. Cellular debris was
removed by centrifugation at 3300 r.p.m. (1100 g) in a 5417R
centrifuge (Eppendorf) at 4°C for 10 min and the supernatant
was mixed 1:1 (v/v) with 2.5-fold concentrated SDS±PAGE
loading buffer (Sambrook and Russell, 2001) containing 4 M
urea (Soulie et al., 1996) and incubated for 10 min at 42°C.
Proteins were separated on a 12% SDS±PAGE gel and blotted
on to a PVDF membrane. Murine anti-tetra-His monoclonal
antibody (Qiagen) was used as a primary antibody and goat
anti-murine F(ab¢)2 conjugated to horseradish peroxidase
(Pierce) as a secondary antibody. Light development using
the ECL cocktail (Amersham Pharmacia Biotech) was detected
by a CCD camera (ChemiImager 5500, Alpha Innotech). No
non-speci®c staining was observed on the western blot,
assessed with the lysate from non-transfected cells.
[35S]GTPg S binding assay
The assay was performed similarly to the described procedure
(Befort et al., 1996; Zhu et al., 1997). Brie¯y, ligands were
added to membranes from transiently transfected HEK293T
cells (2 mg of membrane protein) in 200 ml of incubation buffer
containing 5 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 1 mM
DTT, 0.1% (w/v) BSA, 3 mM GDP and 0.3 nM [35S]GTPgS
(Perkin-Elmer Life Sciences) (1250 Ci/mmol) in 50 mM
HEPES buffer, pH 7.6, and incubated either for 2 h at 4°C or
for 30 min at 30°C. Filtration and a fast wash with 1 ml of ice-
cold washing buffer (5 mM MgCl2, 50 mM NaCl in 50 mM
Tris±HCl, pH 7.5) were performed on a ®ltration plate with
glass-®ber ®lters (MAFBNOB, Millipore) presoaked with
water. Radioactivity remaining on the ®lters was detected as
described above. G-protein activation data were ®tted to a two-
state model by using non-linear least-squares regression in
order to obtain best estimates for EC50 (ligand concentration
needed for half-maximum activation of G-proteins).
Experimental data were normalized by taking the basal
activation in the absence of ligand as a minimum (0%) and
the activation caused by 10 mM Dynorphin A(1±13) as a
maximum (100%).
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Adenylyl cyclase inhibition assay
The 24-well plates were coated with poly-L-lysine (Mr >
300 000; 40 mg/ml) in 150 mM borate buffer, pH 8.4, for 30
min at room temperature. Plates were rinsed twice with water
and stored at ±20°C until used. Stable cell lines were grown in
the coated wells in the selection medium for 28 h, then
naloxone (30 mM) was added and cells were grown for another
20 h. The cells were then washed twice with PBS. Adenylyl
cyclase in the cells was stimulated by forskolin in the presence
of IBMX and inhibited by the action of Gi proteins induced by
agonist according to the protocol used for metabotropic
glutamate receptor type 4 (Flor et al., 1995). Cells were
lysed with 0.1 M HCl (400 ml/well) for 20 min at room
temperature and the resulting extract was stored at ±20°C. Non-
acetylated cyclic AMP (cAMP) was assayed with the direct
cAMP ELISA kit (Sigma, CA-200). Adenylate cyclase activity
data were ®tted similarly to the G-protein activation curves
above. Experimental data were normalized by taking an
adenylate cyclase activity stimulated by forskolin in the
absence of ligand as a maximum (100%) and an adenylate
cyclase activity in the absence of both forskolin and receptor
ligand as a minimum (0%).
Localization of the receptor studied by confocal
¯uorescence microscopy
Cells were seeded on glass coverslips coated with poly-L-lysine
(500 mg/ml). Four hours after transfection, the medium was
exchanged and cells were grown for an additional 20 h in the
presence or absence of naloxone (30 mM). Cells were washed
once with cold HBSS (Hanks' Balanced Salt Solution;
Invitrogen) and incubated with primary antibody [anti-FLAG
M2 antibody diluted 1:1000 (v/v) in HBSS] at 4°C for 60 min,
followed by incubation with HBSS at 4°C for 30 min. Further
incubations took place at room temperature. Cells were ®xed
with 4% (w/v) paraformaldehyde + 4% (w/v) sucrose in PBS,
pH 7.6, for 10 min and blocked with a solution of 10% (v/v)
FCS and 0.1% (w/v) glycine in PBS for 1 h. Donkey anti-
murine antibody conjugate with Cy-3 (contaminant precipitate
was routinely removed by centrifugation) diluted 1:300 (v/v) in
PBS was applied for 45 min. Cells were washed three times
with PBS (15 min incubations) and mounted using Vectashield
mounting medium (Vector Laboratories). Fluorescence images
were acquired using a confocal microscope (Leica TCS SP)
and a 633, 1.32 numerical aperture objective.
Internalization of the receptor studied by confocal
¯uorescence microscopy
Cells were seeded on coated coverslips, transfected and grown
as described above. One day after transfection, cells were
washed twice with PBS and incubated with anti-FLAG M2
antibody for 30 min at 37°C, which allowed for antibody
internalization. Cells were incubated in HBSS for 30 min at
4°C and then ®xed and blocked. Subsequently, cells were
incubated with the secondary antibody for 45 min at room
temperature in PBS containing 3% FCS and 0.1% saponin.
When receptor variants without FLAG tag were studied, goat
anti-KOR antibody diluted 1:100 (N-19, Santa Cruz
Biotechnology, sc-7494) and donkey anti-goat antibody con-
jugate with Texas Red diluted 1:200 were used as primary and
secondary antibodies, respectively. Cells were washed with
PBS, mounted and observed by ¯uorescence microscopy, as
indicated above.
Results
Design of cysteine replacements
Initially, we examined the KOR tertiary structure, which had
been modeled based on geometric distance calculations with
hydrogen bonding constraints (Pogozheva et al., 1997, 1998).
For simplicity, we have numbered the cysteines consecutively
(Figure 1A) and give their corresponding sequence numbers in
Figure 2A. Their positions in the structure are shown
schematically in Figure 1B. It is very likely that Cys131 (C3)
Fig. 1. Schematic representation of cysteines in KOR. Snake-like plot
indicating the trans-membrane a-helices (A) and a model of the tertiary
structure (B) with the indicated cysteines (Pogozheva et al., 1998). Cysteines
are numbered sequentially. For the correspondence to the sequence number,
see Figure 2A.
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and Cys210 (C6) form a disul®de bond. Cys181 (C5) and
Cys229 (C7) seem to be fully exposed to the acyl chains of
phospholipids. Cys161 (C4) resides in the second intracellular
loop. The model suggests several possible interhelical side-
chain interactions for the transmembrane Cys245 (C8) and
Cys315 (C10) within a distance of 3.7±4.0 AÊ .
More information was obtained from the alignment of
sequences of all known members within the GPCR subfamilies
in the GPCR database (http://www.gpcr.org/seq/001/
001.html). Inspired by the success of consensus design
(Knappik et al., 2000; Lehmann et al., 2002), we have
considered the consensus residues in the positions of KOR
cysteines (Figure 2A).
Cysteine replacements
When cysteines C3 or C6 were mutated to alanine,
[3H]diprenorphine binding, measured on whole cells, was
totally lost (Figure 2B). We could not detect any speci®c
Fig. 2. Variation of residues in cysteine positions of KOR. (A) Consensus residue analysis for GPCRs. The most frequent residues and their degree of
conservation are shown for the rhodopsin family and the subfamily of peptide binders. Since the alignment of GPCR sequences does not allow an assessment of
consensus residues in less conserved regions (loops, N- and C-termini), no consensus (minus sign) is indicated for these positions. (B) Expression of His-tagged
receptor mutants with different cysteine substitutions in HEK293T cells. Transfected cells were grown for 20 h in either the absence or presence of naloxone in
the medium. The binding of antagonist [3H]diprenorphine was measured on whole cells. Mock transfections (with the vector without an insert) resulted in only
1% relative speci®c binding compared with the vector with WT KOR.
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binding or mutant receptor labeling at the cell surface even
when naloxone (10 mM) or naltrexone (10 mM) were present in
the growth medium during receptor expression (data not
shown). However, the mutant receptor is expressed in the cell
at a similar level as WT, as assessed by western blotting (data
not shown) and is probably retained in the endoplasmatic
reticulum and/or Golgi apparatus and its size indicates the
absence of complex glycosylation. For this reason, we decided
to keep these two cysteines, which are probably involved in
disul®de bond formation, in the receptor template.
All other cysteine residues could be replaced, resulting in
receptor mutants which bind ligand. A replacement by alanine
is well tolerated in the N- and C-terminal regions of the
receptor (double mutants C1A/C2A and C11A/C12A, respect-
ively). As explained above, other cysteine replacements had to
be designed following structural considerations and by using
consensus design. From testing single and multiple mutants
(Figure 2B), we can conclude that leucine is the best
replacement for cysteines C5 and C7, suspected to face the
lipid bilayer, whereas methionine is the best substitution
among the substitutions tested (Figure 2B) for cysteines C4,
C8, C9 and C10, which all may possibly interact with residues
in other helices. The successful substitution for methionine
indicates that these residues are in an apolar environment and
that it is unlikely that the cysteines are involved in S±H bonds,
otherwise substitutions for threonine or serine would be
expected to be more bene®cial than they are. We found that
we had to test cysteine substitutions by carrying out cell growth
without naloxone, since growth in the presence of naloxone can
rescue the expression of some single mutants, which, in
combination with other mutations, result in a non-functional
receptor. For example, cysteine can be individually replaced at
most positions with alanine and even serine, while the total
alanine FCL receptor or the multiple serine mutant receptor
could not be detected on the cell surface even when the
antagonists naloxone or naltrexone were present during the
expression. Interestingly, these mutants were expressed, but
retained inside the cell, as we had observed for mutants C3A
and C6A (data not shown).
However, naloxone (30 mM) in the growth medium dramat-
ically improves the functional expression of the optimized FCL
receptor (C1A/C2A/C4M/C5L/C7L/C8M/C9M/C10M/C11A/
C12A) almost 20-fold. In contrast, the expression of the WT in
the presence of naloxone was increased by a factor of only 1.3.
When cells are grown in the absence of naloxone, the level of
speci®c ligand binding of the optimized FCL mutant is only 4%
of WT, but it reaches 58% of WT when cells are grown with
naloxone. Clearly, the optimized FCL receptor responds much
more strongly to naloxone in the growth medium. The same
effect of naloxone on the WT and FCL receptors was observed
when the receptors were expressed in COS-1 cells or fused to
an additional N-terminal FLAG tag and C-terminal myc-tag
and expressed in HEK293T cells (see Table I). We also tested
the expression of KOR in cells grown in the presence of
Dynorphin A(1±13) (10 mM) or Peptide I (10 mM); however,
the presence of these ligands in the growth medium did not
signi®cantly affect the expression level of either the WT or
FCL receptor (data not shown).
For the optimized FCL and WT receptors, the binding assay
on whole cells was performed both at room temperature for
45 min (our default set-up) and at 4°C for 4 h to eliminate any
possible effects of receptor internalization on the assay.
However, the ratio of speci®c FCL±receptor binding to
WT±receptor binding did not differ signi®cantly between
these two experimental setups (data not shown).
Ligand-binding characteristics of the WT and FCL receptors
Membrane preparations from cells grown in the presence of
naloxone were used to determine the expression level of
functional receptor (RT) and to estimate the receptor af®nity to
various ligands. RT, determined from different growth experi-
ments, varied for the WT from 2 to 13 pmol/mg and for the
FCL from 1 to 7 pmol/mg (moles of active receptor/mass of
total membrane protein) in transient transfection experiments.
The ratio of RT of the WT to that of the FCL was typically 2:1,
when both receptors were expressed in parallel. Equilibrium
dissociation constants for binding of [3H]diprenorphine to the
WT and FCL receptors are 0.4 6 0.1 and 0.6 6 0.1 nM,
respectively (Figure 3A).
Inhibition of the binding of [3H]diprenorphine by other
opioid receptor ligands is depicted in Figure 3B and C.
Naloxone gave very similar values of 4 6 2 nM for the WT and
6 6 2 nM for the FCL receptor, while the values for agonist
Dynorphin A(1±13) indicated somewhat higher af®nity for WT
(~0.02 6 0.01 nM) than for FCL receptor (0.2 6 0.1 nM). The
af®nities of both WT and FCL KOR for the mu opioid receptor
agonist DAMGO are weak (Ki > 1 mM). The peptidic agonist
Dynorphin A(1±13) competes with radioligand; however, the
single-site binding model (see Materials and methods) does not
properly describe this inhibition. This apparent discrepancy
indicates differential modes for interaction of receptor with
distinct ligands involving subtle changes in receptor conform-
ation. It has been postulated (Chidiac, 2002) that, at steady
state and in the absence of ligand, a GPCR reversibly
isomerizes between the inactive (ground) state and the active
state (G-proteins are activated). It has also been suggested that
an agonist may have a signi®cantly lower af®nity for a receptor
in the inactive state. Furthermore, more than two states of the
receptor may be needed to describe its function. Such
complexities may not be adequately captured by a simple
single-site binding model.
WT and FCL receptor-mediated G-protein activation
We used a [35S]GTPgS binding assay to assess whether the
FCL receptor still couples to G-proteins. Agonist binding
typically leads to receptor internalization (Kallal et al., 1998;
Hasbi et al., 2000; Li et al., 2000) and it was remarkable that
Table I. Expression of WT and FCL KOR in mammalian cellsa
Cells Receptor Fusion Naloxone in growth mediumb
± +
HEK293T WT ± 100c 106
HEK293T WT GFP fusion 77 80
HEK293T FCL ± 2 46
HEK293T FCL GFP fusion 2 36
COS-1 WT ± 100 ND
COS-1 FCL ± 4 51
aFor expression in HEK293T cells, the receptor was fused on its N-terminus
to a FLAG tag and on its C-terminus to a myc-tag followed by a His-tag,
and in some cases to eGFP in front of the myc- and His-tags. For expression
in COS-1 cells, the receptor was fused on its C-terminus to a His-tag only.
bTransfected cells were grown for 20 h in the presence or absence of
naloxone in the medium. The binding of the antagonist [3H]diprenorphine
was measured on whole cells.
cSpeci®c relative binding is given in % of WT.
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the FCL receptor was poorly expressed, except when an
antagonist was added to the growth medium, in which case
almost WT levels were reached. In contrast, the effect of the
antagonist added to the growth medium was small for the
expression of WT KOR. Because of this pronounced effect of
naloxone in the growth medium, it was conceivable that the
FCL receptor behaves, at least to some degree, as a
constitutively active mutant (Li et al., 2001a; McLean et al.,
2002). The WT receptor does activate endogenous G-proteins
present at the membrane of HEK293T cells in an agonist
concentration-dependent manner at 4°C. In contrast, the FCL
receptor appears to be totally inactive at 4°C (not shown).
However, at higher temperature (30°C), both the WT and FCL
receptors activate G-proteins in an agonist concentration-
dependent manner (Figure 4). At this temperature, the basal
activity of G-proteins is increased, making the relative effect of
receptor-mediated activation smaller. However, the basal
activity of the G-proteins was at the same level for the WT
and FCL receptor, when the assay was performed at 4 or 30°C
(data not shown). This indicates that FCL receptor is not a
constitutively active mutant.
Fig. 3. Ligand binding characteristics of KOR. HEK293T cells were
transfected with the receptor fused to the FLAG- (N-terminus) and myc-
followed by His-tag (C-terminus). The cells were grown for 20 h in the
presence of naloxone in the medium. Binding assays were performed with
[3H]diprenorphine and membrane preparations. (A) Saturation binding assay
with WT (®lled squares and dashed ®tted curve) and FCL (open circles and
solid ®tted curve). Binding curves for (B) WT and (C) FCL by displacement
of the radioligand. A ®xed [3H]diprenorphine concentration of 0.25 nM was
used in the presence of various competitors, kappa opioid agonist Dynorphin
A(1±13) (circles), antagonist naloxone (squares) and mu opioid agonist
DAMGO (crosses).
Fig. 4. G-protein coupling for KOR measured by [35S]GTPgS binding
assays. HEK293T cells were transfected with (A) WT and (B) FCL receptor
fused to the FLAG- (N-terminus) and myc- followed by His-tag
(C-terminus). The cells were grown for 20 h in the presence of naloxone in
the medium. Membranes were prepared and [35S]GTPgS binding assays were
performed in the presence of various concentrations of the agonist
Dynorphin A(1±13) at 30°C for 30 min, as described in Materials and
methods.
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The receptor couples to Gi and therefore an agonist causes an
inhibition of adenylyl cyclase activity. Therefore, the accumu-
lation of cAMP in the cell decreases as a function of agonist
action. Forskolin is well known to enhance dramatically the
activity of adenylyl cyclase and thus greatly facilitates the
examination of inhibitory responses. However, forskolin is not
suitable for use with transiently transfected cells, because it
acts on the entire population of cells, including non-transfected
cells (Wong, 1994). We therefore generated isogenic stable cell
lines expressing the WT and FCL receptors using the Flp-InÔ
system (Invitrogen), which is based on the Flp recombinase-
catalyzed insertion of the gene of interest into a single
integrated Flp recombination target site in isogenic Flp-InÔ
cells. A polyclonal selection, in which all survivors are pooled
for subsequent cell expansion, then becomes possible, because
the survivors of the selection can be considered to carry the
gene of interest in an identical position in their genome. We
selected stable cell lines expressing the receptor from inde-
pendent transfections and found that these cell lines express the
receptor at very similar levels, although at lower levels than
observed with transient transfectants (data not shown). A clear
decrease in cAMP accumulation with increasing agonist
concentration is seen for both WT and FCL (Figure 5). From
these experiments, it can be concluded that both the WT and
FCL receptors activate inhibitory G-proteins in living cells at
30°C. The EC50 of agonist Dynorphin A(1±13) is ~0.1 nM for
the WT receptor and 2 nM for the FCL receptor as determined
from the [35S]GTPgS binding assay. The EC50 of the agonist is
~0.3 nM for the WT receptor and ~30 nM for the FCL receptor
as determined using the inhibition of cAMP accumulation
assay. The lower concentration of agonist needed for half-
maximum activation of G-proteins by WT, compared with FCL
receptor (Figures 4 and 5), correlates well with a stronger
agonist binding to WT in radioligand competition assays
(Figure 3B and C).
Localization of the WT and FCL receptors
Western blots (Figure 6) show the overall cellular expression
levels of the receptors, which are comparable for the WT and
FCL receptors and are unaffected by the addition of naloxone
into the medium (lanes 2 and 4). The anti-tetra-His antibody is
highly selective and when we analyzed a control extract from
cells transfected with a vector without an insert, only one very
faint band at ~70 kDa was detected, while the receptor bands
(43±60 kDa) were absent (lane 5). The major band at an
apparent Mr of 43 kDa (lanes 1±4), which corresponds to a full-
length receptor without complex glycans, probably indicates
receptor retained in the internal cellular stores (endoplasmic
reticulum, Golgi apparatus and inclusion bodies). The presence
of naloxone in the growth medium also had no signi®cant
effect on the expression pattern, e.g. bands corresponding to
the full-length receptor, degradation products or any oligomers,
as seen on the western blot (lanes 2 and 4). Receptor forms with
Fig. 5. G-protein coupling for KOR monitored by Gi protein-mediated
inhibition of adenylyl cyclase. Stable cell lines expressing (A) WT and
(B) FCL receptor in Flp-HEK293Ô cells were grown for 20 h in the
presence of naloxone and stimulated with forskolin in the presence of
various concentrations of agonist Dynorphin A(1±13) at 30°C for 20 min, as
described in Materials and methods.
Fig. 6. Expression of KOR in HEK293T cells. HEK293T cells were
transfected with WT (lanes 1 and 2) and FCL (lanes 3 and 4) receptor fused
to the FLAG- (N-terminus) and myc- followed by His-tag (C-terminus). The
cells were grown for 20 h in the absence (lanes 1 and 3) or presence (lanes 2
and 4) of naloxone in the medium. Proteins from whole cell lysates were
resolved by SDS±PAGE, blotted on to a PVDF membrane and detected
using an anti-His tag antibody. Lane 5 corresponds to cells transfected with
the vector without an insert and lane 6 corresponds to High-range Rainbow
Molecular Weight Marker (Amersham Biosciences).
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complex glycosylation could not be clearly detected even for
the WT, probably owing to the relatively low abundance of
receptor correctly inserted into the plasma membrane when
compared with the total amount of receptor accumulated inside
the cell.
Cytoimmunochemistry provided further information on
receptor localization and dynamics. We fused eGFP
(Lippincott-Schwartz and Patterson, 2003) to the C-termini
of the WT and FCL receptors. Fused eGFP did not signi®cantly
affect either [3H]diprenorphine binding (Table I) or inhibition
of radioligand binding by Dynorphin A(1±13) or by naloxone
or agonist-induced G-protein activation using [35S]GTPgS
(data not shown). Similar observations were reported recently
for the WT KOR (Ramsay et al., 2002; Schulz et al., 2002).
Cells expressing the WT and FCL receptors, each carrying an
N-terminal FLAG tag and a C-terminal eGFP moiety, were
labeled with anti-FLAG M2 antibody at 4°C for 1 h, conditions
under which internalization can be neglected. In these experi-
ments, the WT receptor was present on the plasma membrane
(seen both by eGFP ¯uorescence and by anti-FLAG tag
detection) and also in internal stores (seen only by eGFP
¯uorescence) (images A2 and A3 in Figure 7). Naloxone
slightly increased the concentration of WT in the plasma
membrane (compare A3 and B3). In contrast, when the FCL
receptor was expressed in the absence of naloxone, the
antibody did not label the cell surface (image C3). The mutant
is, however, detected in the internal cellular stores, by its eGFP
¯uorescence, at a level similar to WT (image C2). Strikingly,
when cells were grown in the presence of naloxone, the mutant
was clearly detectable both on the cell surface and in the
internal stores (images D2 and D3). This completely mirrors
the effects seen in the ligand-binding experiments (see above)
(Figure 2B, Table I). We conclude that naloxone stabilizes the
FCL mutant on the cell surface.
A different experimental set-up was also employed
(Figure 8), in which cells expressing the N-terminally FLAG-
tagged receptor without eGFP were incubated at 37°C for 30
min (promoting internalization) in the presence of anti-FLAG
M2 antibody and then ®xed. They were later stained with a
labeled secondary antibody under conditions where mem-
branes and vesicles were permeabilized. The WT receptor was
mainly located on the plasma membrane and there was no
remarkable difference between cell growth in the presence or
absence of naloxone (Figure 8, images A2 and B2). When
naloxone was omitted during the FCL receptor expression, the
plasma membrane was not stained. In this case, stained vesicles
were observed inside the cells (image C2). However, when
these cells were grown in the presence of naloxone, the FCL
receptor was also present on the plasma membrane (image D2).
Taken together, we infer that the FCL receptor is properly
targeted to the plasma membrane, but it does not stay there and
is quickly internalized. Naloxone signi®cantly decreases the
rate of internalization.
Discussion
We have engineered a mutant of the KOR with 10 exchanged
residues. The mutant, devoid of all free cysteines, is functional
in agonist and antagonist binding and was shown to activate
Fig. 7. Localization of KOR in HEK293T cells. FLAG- and eGFP-tagged WT (rows A and B) and FCL (rows C and D) receptors were expressed in HEK293T
cells. The cells were stained with an anti-FLAG antibody at 4°C and subsequently with a Cy-3-labeled secondary antibody. Cells were grown either in the
absence of naloxone (rows A and C) or in its presence (rows B and D) in the growth medium. Phase contrast (column 1), eGFP ¯uorescence (column 2),
anti-FLAG detection (Cy-3 ¯uorescence; column 3) and merged images (column 4). Scale bar: 10 mm.
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G-proteins for GDP/GTP exchange and to signal by inhibiting
adenylyl cyclase. While binding of antagonists was indistin-
guishable from WT, there are subtle differences in agonist
binding, in the temperature dependence of G-protein activation
and, most strikingly, in receptor internalization in the absence
of agonist. A good correlation was observed for both receptors
between radioligand binding and labeling on the cell surface, as
detected by ¯uorescence microscopy, and this provided
evidence for pronounced constitutive internalization of the
FCL receptor.
When designing the sulfhydryl-free receptor, the ®rst
problem was to determine the appropriate substitutions for 10
free cysteines of the WT, which occur in the N-terminal region,
the transmembrane helices, the second cytoplasmic loop and
the cytoplasmic tail. Typically, cysteine has been replaced by
alanine and serine. Cysteine is a hydrophobic residue, which,
under certain circumstances, can form a hydrogen bond (Raso
et al., 2001), but serine does not seem to be a very suitable
replacement because of its high polarity. Nevertheless, many
receptors tolerate the replacement of one or even multiple
endogenous cysteines with serine, but do not tolerate all
substitutions at once (Gaibelet et al., 1997; Gether et al., 1997;
Ehrlich et al., 1998; Zeng et al., 1999; Scholl and Wells, 2000;
Xu et al., 2000; Ponimaskin et al., 2002). We also found that a
complete cysteine replacement with alanines did not yield a
functional molecule, even when the putative disul®de bond is
retained. An inspection of the KOR model suggested replace-
ment of cysteines with a hydrophobic residue in the case of C5
and C7, which are likely to be exposed to phospholipids, and
our choice was leucine, which is the GPCR family consensus
residue in these positions. Threonine is a consensus residue for
C10. Consensus residues in the positions of the transmembrane
cysteines in KOR are indeed often cysteines (in positions C3,
C8 and C9), which indicate the spatial and possibly functional
role of cysteine at these transmembrane positions. We cannot
conclude that our engineered cysteine substitutions are the
optimal ones. Nevertheless, the WT and optimized FCL
receptors feature almost the same binding characteristics to
the ligands tested and the measured af®nities are similar to
published binding data for KOR (Goldstein and Naidu, 1989;
Meng et al., 1993; Yasuda et al., 1993; Raynor et al., 1994).
However, the FCL receptor has about a 10-fold lower
af®nity for the agonist Dynorphin A(1±13) compared with WT.
Similarly, the EC50 of Dynorphin A(1±13) for activation of
G-proteins via the FCL receptor is about 20±100 times higher
than in the case of the WT. It should be stressed that our aim
was to express functionally both WT and FCL receptor at
comparable levels for all assays. Hence the [35S]GTPgS
binding assay was performed with membranes from the cells
grown in the presence of naloxone and we also grew the cells
prior to the cAMP accumulation assay in the presence of
naloxone. We could not characterize FCL receptor that had
been expressed in the absence of naloxone in the medium,
because there was very little FCL receptor in the plasma
membrane under these conditions. There is a dramatic
difference in the stabilities of the WT and FCL receptors on
the cell surface in vivo and this difference can be suppressed by
adding naloxone to the growth medium. This phenomenon was
observed in both HEK293T and COS-1 cells.
The fact that all of these differences between the WT and
FCL receptors are rather subtle suggests that both receptor
variants have very similar conformations in both the active and
inactive receptor signaling states (Chidiac, 2002), but the
inactive conformation of the FCL receptor needs to be
stabilized by naloxone. Unstabilized FCL receptor is quickly
eliminated from the plasma membrane (Figure 8). It is possible
that this is mostly due to a lack of palmitoylation. Note that the
C-terminal cysteines C11 and C12, when both substituted to
alanine, have only a small effect on receptor expression and
that the low expression of FCL receptor and its ef®cient rescue
with naloxone are re¯ected in the properties of KOR with
mutated C4 (Figure 2B). It has been suggested (Chen et al.,
1998) that the opioid receptors are not palmitoylated in the
C-terminal tail, but instead in the second intracellular loop,
where C4 in KOR is located. It is conceivable that this mutation
alters the af®nity to G-proteins and has important conse-
quences for receptor phosphorylation and internalization,
probably involving G protein-coupled receptor kinase and/or
b-arrestin, known adaptors of human KOR internalization
(Li,J., et al., 2002; Schulz et al., 2002). This behavior is
reminiscent of MOR, which has been mutated in the conserved
DRY motif, located in the beginning of the second intracellular
loop. The mutant MOR was found to be constitutively
internalized via G protein-coupled receptor kinase-, b-arrest-
in-, dynamin-, rab5- and rab7-dependent pathways (Li et al.,
2001a). We also cannot completely rule out the possibility that
the FCL receptor has a slightly altered oligomerization state
Fig. 8. Internalization of KOR in HEK293T cells. FLAG-tagged WT (rows
A and B) and FCL (rows C and D) receptors were expressed in HEK293T
cells. The cells were stained with an anti-FLAG antibody at 37°C and
subsequently with a Cy-3-labeled secondary antibody in the presence of
saponin. Cells were grown either in the absence of naloxone (rows A and C)
or in its presence (rows B and D) in the growth medium. Phase contrast
(column 1) and anti-FLAG detection (Cy-3 ¯uorescence; column 2). Scale
bar: 10 mm.
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compared with the WT receptor; however, we did not observe
any qualitative difference in the receptor expression pro®les on
western blots. Therefore, we propose that the FCL receptor
behaves like the WT receptor with respect to its signaling
functions.
Our constructed receptor, devoid of free endogenous
cysteines, now opens the door to a number of studies in
which these cysteines would have been problematic. For
example, the introduction of ¯uorescent labels at any position
in the receptor now becomes possible, to detect conformational
changes or local binding events. Many possibilities for directed
immobilization become available. Finally, receptor folding is
greatly simpli®ed, as the only two remaining cysteines
probably form a disul®de bond, but no disul®de scrambling
can occur. This strategy may help in the future biophysical
characterization of GPCRs.
Acknowledgements
The authors thank Dr Casim Sarkar for valuable assistance with the data
evaluation and for careful reading of the manuscript and Dr Annemarie
Honegger for help with preparation of the ®gures. This work was supported by
the National Center for Competence in Research in Structural Biology and by
the TopNano21 Project (KTI, Bern, Switzerland).
References
Appleyard,S.M., Celver,J., Pineda,V., Kovoor,A., Wayman,G.A. and
Chavkin,C. (1999) J. Biol. Chem., 274, 23802±23807.
Becker,J.A., Wallace,A., Garzon,A., Ingallinella,P., Bianchi,E., Cortese,R.,
Simonin,F., Kieffer,B.L. and Pessi,A. (1999) J. Biol. Chem., 274,
27513±27522.
Befort,K., Tabbara,L. and Kieffer,B.L. (1996) Neurochem. Res., 21,
1301±1307.
Blumberg,H., Dayton,H.B., George,M. and Rapaport,D.N. (1961) Fed. Proc.,
20, 311.
Brugge,J.S. and Erikson,R.L. (1977) Nature, 269, 346±348.
Bruns,R.F., Lawson-Wendling,K. and Pugsley,T.A. (1983) Anal. Biochem.,
132, 74±81.
Chen,C., Xue,J.C., Zhu,J., Chen,Y.W., Kunapuli,S., Kim de Riel,J., Yu,L. and
Liu-Chen,L.Y. (1995) J. Biol. Chem., 270, 17866±17870.
Chen,C., Shahabi,V., Xu,W. and Liu-Chen,L.Y. (1998) FEBS Lett., 441,
148±152.
Chidiac,P. (2002) Methods Enzymol., 343, 3±16.
Coward,P., Wada,H.G., Falk,M.S., Chan,S.D., Meng,F., Akil,H. and
Conklin,B.R. (1998) Proc. Natl Acad. Sci. USA, 95, 352±357.
Demoliou-Mason,C.D. and Barnard,E.A. (1986) J. Neurochem., 46,
1129±1136.
Ehrlich,G.K., Andria,M.L., Zheng,X., Kieffer,B., Gioannini,T.L., Hiller,J.M.,
Rosenkranz,J.E., Veksler,B.M., Zukin,R.S. and Simon,E.J. (1998) Can. J.
Physiol. Pharmacol., 76, 269±277.
Flor,P.J., Lukic,S., Ruegg,D., Leonhardt,T., Knopfel,T. and Kuhn,R. (1995)
Neuropharmacology, 34, 149±155.
Foldes,F.F., Lunn,J.N., Moore,J. and Brown,I.M. (1963) Am. J. Med. Sci., 245,
23±30.
Gaibelet,G., Capeyrou,R., Dietrich,G. and Emorine,L.J. (1997) FEBS Lett.,
408, 135±140.
Gether,U., Lin,S. and Kobilka,B.K. (1995) J. Biol. Chem., 270, 28268±28275.
Gether,U., Lin,S., Ghanouni,P., Ballesteros,J.A., Weinstein,H. and
Kobilka,B.K. (1997) EMBO J., 16, 6737±6747.
Ghanouni,P., Steenhuis,J.J., Farrens,D.L. and Kobilka,B.K. (2001) Proc. Natl
Acad. Sci. USA, 98, 5997±6002.
Gioannini,T.L., Howard,A.D., Hiller,J.M. and Simon,E.J. (1985) J. Biol.
Chem., 260, 15117±15121.
Gioannini,T.L., Liu,Y.F., Park,Y.H., Hiller,J.M. and Simon,E.J. (1989) J. Mol.
Recognit., 2, 44±48.
Goldstein,A. (1984). Biology and Chemistry of the Dynorphin Peptides, Vol.
6. Academic Press, New York.
Goldstein,A. and Naidu,A. (1989) Mol. Pharmacol., 36, 265±272.
Graham,F.L. and van der Eb,A.J. (1973) Virology, 52, 456±467.
Hasbi,A., Allouche,S., Sichel,F., Stanasila,L., Massotte,D., Landemore,G.,
Polastron,J. and Jauzac,P. (2000) J. Pharmacol. Exp. Ther., 293, 237±247.
Hjorth,S.A., Thirstrup,K., Grandy,D.K. and Schwartz,T.W. (1995) Mol.
Pharmacol., 47, 1089±1094.
Hjorth,S.A., Thirstrup,K. and Schwartz,T.W. (1996) Mol. Pharmacol., 50,
977±984.
Itzhak,Y., Hiller,J.M. and Simon,E.J. (1984) Proc. Natl Acad. Sci. USA, 81,
4217±4221.
Javitch,J.A., Shi,L. and Liapakis,G. (2002) Methods Enzymol., 343, 137±156.
Jones,R.M., Hjorth,S.A., Schwartz,T.W. and Portoghese,P.S. (1998) J. Med.
Chem., 41, 4911±4914.
Kallal,L., Gagnon,A.W., Penn,R.B. and Benovic,J.L. (1998) J. Biol. Chem.,
273, 322±328.
Knappik,A., Ge,L., Honegger,A., Pack,P., Fischer,M., Wellnhofer,G.,
Hoess,A., WoÈlle,J., PluÈckthun,A. and VirnekaÈs,B. (2000) J. Mol. Biol.,
296, 57±86.
Kong,H., Raynor,K., Yano,H., Takeda,J., Bell,G.I. and Reisine,T. (1994)
Proc. Natl Acad. Sci. USA, 91, 8042±8046.
Lehmann,M., Loch,C., Middendorf,A., Studer,D., Lassen,S.F., Pasamontes,L.,
van Loon,A.P. and Wyss,M. (2002) Protein Eng., 15, 403±411.
Li,J., Chen,C., Huang,P. and Liu-Chen,L.Y. (2001) Mol. Pharmacol., 60,
1064±1075.
Li,J., Huang,P., Chen,C., de Riel,J.K., Weinstein,H. and Liu-Chen,L.Y.
(2001b) Biochemistry (Mosc.), 40, 12039±12050.
Li,J., Li,J.G., Chen,C., Zhang,F. and Liu-Chen,L.Y. (2002) Mol. Pharmacol.,
61, 73±84.
Li,J.G., Benovic,J.L. and Liu-Chen,L.Y. (2000) Mol. Pharmacol., 58,
795±801.
Li,J.G., Chen,C. and Liu-Chen,L.Y. (2002) J. Biol. Chem., 277, 27545±27552.
Lippincott-Schwartz,J. and Patterson,G.H. (2003) Science, 300, 87±91.
Liu,J., Schoneberg,T., van Rhee,M. and Wess,J. (1995) J. Biol. Chem., 270,
19532±19539.
Lu,Y.F., et al. (1998) Synapse, 28, 117±124.
McLean,A.J., Zeng,F.Y., Behan,D., Chalmers,D. and Milligan,G. (2002) Mol.
Pharmacol., 62, 747±755.
Meng,F., Xie,G.X., Thompson,R.C., Mansour,A., Goldstein,A., Watson,S.J.
and Akil,H. (1993) Proc. Natl Acad. Sci. USA, 90, 9954±9958.
Meng,F., Hoversten,M.T., Thompson,R.C., Taylor,L., Watson,S.J. and Akil,H.
(1995) J. Biol. Chem., 270, 12730±12736.
Meng,F., Ueda,Y., Hoversten,M.T., Thompson,R.C., Taylor,L., Watson,S.J.
and Akil,H. (1996) Eur. J. Pharmacol., 311, 285±292.
Minami,M., Toya,T., Katao,Y., Maekawa,K., Nakamura,S., Onogi,T.,
Kaneko,S. and Satoh,M. (1993) FEBS Lett., 329, 291±295.
Minami,M., Onogi,T., Nakagawa,T., Katao,Y., Aoki,Y., Katsumata,S. and
Satoh,M. (1995) FEBS Lett., 364, 23±27.
Mollereau,C., Mouledous,L., Lapalu,S., Cambois,G., Moisand,C., Butour,J.L.
and Meunier,J.C. (1999) Mol. Pharmacol., 55, 324±331.
Neumann,L., Wohland,T., Whelan,R.J., Zare,R.N. and Kobilka,B.K. (2002)
Chembiochem, 3, 993±998.
O'Gorman,S., Fox,D.T. and Wahl,G.M. (1991) Science, 251, 1351±1355.
Pogozheva,I.D., Lomize,A.L. and Mosberg,H.I. (1997) Biophys. J., 72,
1963±1985.
Pogozheva,I.D., Lomize,A.L. and Mosberg,H.I. (1998) Biophys. J., 75,
612±634.
Ponimaskin,E.G., Heine,M., Joubert,L., Sebben,M., Bickmeyer,U.,
Richter,D.W. and Dumuis,A. (2002) J. Biol. Chem., 277, 2534±2546.
Prather,P.L., McGinn,T.M., Claude,P.A., Liu-Chen,L.Y., Loh,H.H. and
Law,P.Y. (1995) Brain Res. Mol. Brain Res., 29, 336±346.
Ramsay,D., Kellett,E., McVey,M., Rees,S. and Milligan,G. (2002) Biochem.
J., 365, 424±440.
Raso,S.W., Clark,P.L., Haase-Pettingell,C., King,J. and Thomas,G.J.,Jr.
(2001) J. Mol. Biol., 307, 899±911.
Raynor,K., Kong,H., Chen,Y., Yasuda,K., Yu,L., Bell,G.I. and Reisine,T.
(1994) Mol. Pharmacol., 45, 330±334.
Reece,P.A., Sedman,A.J., Rose,S., Wright,D.S., Dawkins,R. and
Rajagopalan,R. (1994) J. Clin. Pharmacol., 34, 1126±1132.
Ruegg,U.T., Cuenoud,S., Fulpius,B.W. and Simon,E.J. (1982) Biochim.
Biophys. Acta, 685, 241±248.
Sambrook,J. and Russell,D.W. (eds) (2001). Molecular Cloning. A Laboratory
Manual. 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY.
Satoh,M. and Minami,M. (1995) Pharmacol. Ther., 68, 343±364.
Scholl,D.J. and Wells,J.N. (2000) Biochem. Pharmacol., 60, 1647±1654.
Schulz,R., Wehmeyer,A. and Schulz,K. (2002) Mol. Pharmacol., 61,
1444±1452.
Seki,T., Minami,M., Nakagawa,T., Ienaga,Y., Morisada,A. and Satoh,M.
(1998) Eur. J. Pharmacol., 350, 301±310.
Simon,J., Benyhe,S., Borsodi,A., Szucs,M. and Wollemann,M. (1985) FEBS
Lett., 183, 395±397.
Kappa opioid receptor devoid of all free cysteines
47
Simon,J., Benyhe,S., Abutidze,K., Borsodi,A., Szucs,M., Toth,G. and
Wollemann,M. (1986) J. Neurochem., 46, 695±701.
Simon,J., Benyhe,S., Hepp,J., Khan,A., Borsodi,A., Szucs,M.,
Medzihradszky,K. and Wollemann,M. (1987) Neuropeptides, 10, 19±28.
Soulie,S., Moller,J.V., Falson,P. and le Maire,M. (1996) Anal. Biochem., 236,
363±364.
Standifer,K.M. and Pasternak,G.W. (1997) Cell. Signal., 9, 237±248.
Thirstrup,K., Elling,C.E., Hjorth,S.A. and Schwartz,T.W. (1996) J. Biol.
Chem., 271, 7875±7878.
Tso,P.H. and Wong,Y.H. (2000) J. Pharmacol. Exp. Ther., 295, 168±176.
Wang,J.B., Johnson,P.S., Wu,J.M., Wang,W.F. and Uhl,G.R. (1994) J. Biol.
Chem., 269, 25966±25969.
Ward,S.D., Hamdan,F.F., Bloodworth,L.M. and Wess,J. (2002) J. Biol. Chem.,
277, 2247±2257.
Wong,Y.H. (1994) Methods Enzymol., 238, 81±94.
Xu,W., Chen,C., Huang,P., Li,J., de Riel,J.K., Javitch,J.A. and Liu-Chen,L.Y.
(2000) Biochemistry (Mosc.), 39, 13904±13915.
Xu,W., Li,J., Chen,C., Huang,P., Weinstein,H., Javitch,J.A., Shi,L., de
Riel,J.K. and Liu-Chen,L.Y. (2001) Biochemistry (Mosc.), 40, 8018±8029.
Xue,J.C., Chen,C., Zhu,J., Kunapuli,S., DeRiel,J.K., Yu,L. and Liu-Chen,L.Y.
(1994) J. Biol. Chem., 269, 30195±30199.
Xue,J.C., Chen,C., Zhu,J., Kunapuli,S.P., de Riel,J.K., Yu,L. and Liu-
Chen,L.Y. (1995) J. Biol. Chem., 270, 12977±12979.
Yasuda,K., Raynor,K., Kong,H., Breder,C.D., Takeda,J., Reisine,T. and
Bell,G.I. (1993) Proc. Natl Acad. Sci. USA, 90, 6736±6740.
Zeng,F.Y., Hopp,A., Soldner,A. and Wess,J. (1999) J. Biol. Chem., 274,
16629±16640.
Zhang,F., Li,J., Li,J.G. and Liu-Chen,L.Y. (2002) J. Pharmacol. Exp. Ther.,
302, 1184±1192.
Zhang,P., Johnson,P.S., ZoÈllner,C., Wang,W., Wang,Z., Montes,A.E.,
Seidleck,B.K., Blaschak,C.J. and Surratt,C.K. (1999) Brain Res. Mol.
Brain Res., 72, 195±204.
Zhu,J., Xue,J.C., Law,P.Y., Claude,P.A., Luo,L.Y., Yin,J., Chen,C. and Liu-
Chen,L.Y. (1996) FEBS Lett., 384, 198±202.
Zhu,J., Luo,L.Y., Li,J.G., Chen,C. and Liu-Chen,L.Y. (1997) J. Pharmacol.
Exp. Ther., 282, 676±684.
Received September 11, 2003; accepted October 16, 2003
Edited by Alan Fersht
D.Ott, R.Frischknecht and A.PluÈckthun
48
